379
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma

, ORCID Icon, ORCID Icon, , , , , , , ORCID Icon & show all
Pages 17-26 | Received 11 Aug 2022, Accepted 04 Jan 2023, Published online: 11 Jan 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Shao YY, Wang SY, Lin SM, Diagnosis G, Systemic Therapy G. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021;120(4):1051–1060. doi:10.1016/j.jfma.2020.10.031
  • European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
  • Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol. 2016;65(6):1148–1154. doi:10.1016/j.jhep.2016.07.025
  • Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–63 e2. doi:10.1053/j.gastro.2016.08.029
  • Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1000-patient 15-year experience. Hepatology. 2018;68(4):1429–1440. doi:10.1002/hep.29691
  • Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
  • Tabone M, Calvo A, Russolillo N, et al. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. J Gastrointest Oncol. 2020;11(1):84–90. doi:10.21037/jgo.2019.06.01
  • Gabr A, Kulik L, Mouli S, et al. Liver transplantation following Yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology. 2021;73(3):998–1010. doi:10.1002/hep.31318
  • Kamarajah SK, Frankel TL, Sonnenday C, Cho CS, Nathan H. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): a Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol. 2018;117(4):644–650. doi:10.1002/jso.24908
  • Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13–23. doi:10.1016/j.ijrobp.2006.11.060
  • Levillain H, Bagni O, Deroose CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570–1584. doi:10.1007/s00259-020-05163-5
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
  • Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–430. doi:10.1016/S0168-8278(01)00130-1
  • Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112(1):90–92. doi:10.1016/j.ad.2019.05.009
  • Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled Phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. doi:10.1016/S1470-2045(17)30683-6
  • Levillain H, Duran Derijckere I, Ameye L, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270–2279. doi:10.1007/s00259-019-04427-z
  • Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687–3694. doi:10.1200/JCO.2010.28.5643
  • Saini A, Wallace A, Alzubaidi S, et al. History and evolution of Yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med. 2019;8(1). doi:10.3390/jcm8010055
  • De la Garza-Ramos C, Overfield CJ, Montazeri SA, et al. Biochemical safety of ablative Yttrium-90 radioembolization for hepatocellular carcinoma as a function of percent liver treated. J Hepatocell Carcinoma. 2021;8:861–870. doi:10.2147/JHC.S319215
  • Lee SY, Ou HY, Yu CY, Huang TL, Tsang LL, Cheng YF. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter? Diagn Interv Radiol. 2020;26(3):230–235. doi:10.5152/dir.2019.19261
  • Chaminda SR, Suchintha T, Anuk NM, et al. Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology - a prospective study. BMC Gastroenterol. 2017;17(1):142. doi:10.1186/s12876-017-0710-x
  • Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25(7):455–461. doi:10.1007/s12149-011-0499-6
  • Yim SY, Chun HS, Lee JS, et al. Transarterial radioembolization for unresectable hepatocellular carcinoma: real-life efficacy and safety analysis of Korean patients. Cancers. 2022;14(2). doi:10.3390/cancers14020385